These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
875 related articles for article (PubMed ID: 22572202)
1. Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial. Easton JD; Lopes RD; Bahit MC; Wojdyla DM; Granger CB; Wallentin L; Alings M; Goto S; Lewis BS; Rosenqvist M; Hanna M; Mohan P; Alexander JH; Diener HC; Lancet Neurol; 2012 Jun; 11(6):503-11. PubMed ID: 22572202 [TBL] [Abstract][Full Text] [Related]
2. Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial. Diener HC; Eikelboom J; Connolly SJ; Joyner CD; Hart RG; Lip GY; O'Donnell M; Hohnloser SH; Hankey GJ; Shestakovska O; Yusuf S; Lancet Neurol; 2012 Mar; 11(3):225-31. PubMed ID: 22305462 [TBL] [Abstract][Full Text] [Related]
3. Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Hankey GJ; Patel MR; Stevens SR; Becker RC; Breithardt G; Carolei A; Diener HC; Donnan GA; Halperin JL; Mahaffey KW; Mas JL; Massaro A; Norrving B; Nessel CC; Paolini JF; Roine RO; Singer DE; Wong L; Califf RM; Fox KA; Hacke W; Lancet Neurol; 2012 Apr; 11(4):315-22. PubMed ID: 22402056 [TBL] [Abstract][Full Text] [Related]
4. Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial. Jaspers Focks J; Brouwer MA; Wojdyla DM; Thomas L; Lopes RD; Washam JB; Lanas F; Xavier D; Husted S; Wallentin L; Alexander JH; Granger CB; Verheugt FW BMJ; 2016 Jun; 353():i2868. PubMed ID: 27306620 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial. Lopes RD; Al-Khatib SM; Wallentin L; Yang H; Ansell J; Bahit MC; De Caterina R; Dorian P; Easton JD; Erol C; Ezekowitz JA; Gersh BJ; Granger CB; Hohnloser SH; Horowitz J; Hylek EM; McMurray JJ; Mohan P; Vinereanu D; Alexander JH Lancet; 2012 Nov; 380(9855):1749-58. PubMed ID: 23036896 [TBL] [Abstract][Full Text] [Related]
6. Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial. Alexander JH; Lopes RD; Thomas L; Alings M; Atar D; Aylward P; Goto S; Hanna M; Huber K; Husted S; Lewis BS; McMurray JJ; Pais P; Pouleur H; Steg PG; Verheugt FW; Wojdyla DM; Granger CB; Wallentin L Eur Heart J; 2014 Jan; 35(4):224-32. PubMed ID: 24144788 [TBL] [Abstract][Full Text] [Related]
7. Apixaban 5 mg Twice Daily and Clinical Outcomes in Patients With Atrial Fibrillation and Advanced Age, Low Body Weight, or High Creatinine: A Secondary Analysis of a Randomized Clinical Trial. Alexander JH; Andersson U; Lopes RD; Hijazi Z; Hohnloser SH; Ezekowitz JA; Halvorsen S; Hanna M; Commerford P; Ruzyllo W; Huber K; Al-Khatib SM; Granger CB; Wallentin L; JAMA Cardiol; 2016 Sep; 1(6):673-81. PubMed ID: 27463942 [TBL] [Abstract][Full Text] [Related]
8. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack. Coleman CI; Peacock WF; Bunz TJ; Alberts MJ Stroke; 2017 Aug; 48(8):2142-2149. PubMed ID: 28655814 [TBL] [Abstract][Full Text] [Related]
9. Apixaban in patients with atrial fibrillation and prior coronary artery disease: insights from the ARISTOTLE trial. Bahit MC; Lopes RD; Wojdyla DM; Hohnloser SH; Alexander JH; Lewis BS; Aylward PE; Verheugt FW; Keltai M; Diaz R; Hanna M; Granger CB; Wallentin L Int J Cardiol; 2013 Dec; 170(2):215-20. PubMed ID: 24192334 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. Wallentin L; Lopes RD; Hanna M; Thomas L; Hellkamp A; Nepal S; Hylek EM; Al-Khatib SM; Alexander JH; Alings M; Amerena J; Ansell J; Aylward P; Bartunek J; Commerford P; De Caterina R; Erol C; Harjola VP; Held C; Horowitz JD; Huber K; Husted S; Keltai M; Lanas F; Lisheng L; McMurray JJ; Oh BH; Rosenqvist M; Ruzyllo W; Steg PG; Vinereanu D; Xavier D; Granger CB; Circulation; 2013 Jun; 127(22):2166-76. PubMed ID: 23640971 [TBL] [Abstract][Full Text] [Related]
11. High-sensitivity troponin T and risk stratification in patients with atrial fibrillation during treatment with apixaban or warfarin. Hijazi Z; Wallentin L; Siegbahn A; Andersson U; Alexander JH; Atar D; Gersh BJ; Hanna M; Harjola VP; Horowitz JD; Husted S; Hylek EM; Lopes RD; McMurray JJ; Granger CB; J Am Coll Cardiol; 2014 Jan 7-14; 63(1):52-61. PubMed ID: 24055845 [TBL] [Abstract][Full Text] [Related]
12. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Diener HC; Connolly SJ; Ezekowitz MD; Wallentin L; Reilly PA; Yang S; Xavier D; Di Pasquale G; Yusuf S; Lancet Neurol; 2010 Dec; 9(12):1157-1163. PubMed ID: 21059484 [TBL] [Abstract][Full Text] [Related]
13. Clinical outcomes in patients with atrial fibrillation according to sex during anticoagulation with apixaban or warfarin: a secondary analysis of a randomized controlled trial. Vinereanu D; Stevens SR; Alexander JH; Al-Khatib SM; Avezum A; Bahit MC; Granger CB; Lopes RD; Halvorsen S; Hanna M; Husted S; Hylek EM; Mărgulescu AD; Wallentin L; Atar D Eur Heart J; 2015 Dec; 36(46):3268-75. PubMed ID: 26371113 [TBL] [Abstract][Full Text] [Related]
14. High-sensitivity troponin I for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Hijazi Z; Siegbahn A; Andersson U; Granger CB; Alexander JH; Atar D; Gersh BJ; Mohan P; Harjola VP; Horowitz J; Husted S; Hylek EM; Lopes RD; McMurray JJ; Wallentin L; Circulation; 2014 Feb; 129(6):625-34. PubMed ID: 24226808 [TBL] [Abstract][Full Text] [Related]
15. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes. Hylek EM; Held C; Alexander JH; Lopes RD; De Caterina R; Wojdyla DM; Huber K; Jansky P; Steg PG; Hanna M; Thomas L; Wallentin L; Granger CB J Am Coll Cardiol; 2014 May; 63(20):2141-2147. PubMed ID: 24657685 [TBL] [Abstract][Full Text] [Related]
16. Amiodarone, anticoagulation, and clinical events in patients with atrial fibrillation: insights from the ARISTOTLE trial. Flaker G; Lopes RD; Hylek E; Wojdyla DM; Thomas L; Al-Khatib SM; Sullivan RM; Hohnloser SH; Garcia D; Hanna M; Amerena J; Harjola VP; Dorian P; Avezum A; Keltai M; Wallentin L; Granger CB; J Am Coll Cardiol; 2014 Oct; 64(15):1541-50. PubMed ID: 25301455 [TBL] [Abstract][Full Text] [Related]
17. Apixaban versus warfarin in patients with atrial fibrillation according to prior warfarin use: results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial. Garcia DA; Wallentin L; Lopes RD; Thomas L; Alexander JH; Hylek EM; Ansell J; Hanna M; Lanas F; Flaker G; Commerford P; Xavier D; Vinereanu D; Yang H; Granger CB Am Heart J; 2013 Sep; 166(3):549-58. PubMed ID: 24016506 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation and Peripheral Artery Disease: Insights From the ARISTOTLE Trial. Hu PT; Lopes RD; Stevens SR; Wallentin L; Thomas L; Alexander JH; Hanna M; Lewis BS; Verheugt FW; Granger CB; Jones WS J Am Heart Assoc; 2017 Jan; 6(1):. PubMed ID: 28096100 [TBL] [Abstract][Full Text] [Related]
19. Apixaban in Comparison With Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: Findings From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. Avezum A; Lopes RD; Schulte PJ; Lanas F; Gersh BJ; Hanna M; Pais P; Erol C; Diaz R; Bahit MC; Bartunek J; De Caterina R; Goto S; Ruzyllo W; Zhu J; Granger CB; Alexander JH Circulation; 2015 Aug; 132(8):624-32. PubMed ID: 26106009 [TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation in Relation to Renal Function Over Time: Insights From the ARISTOTLE Randomized Clinical Trial. Hijazi Z; Hohnloser SH; Andersson U; Alexander JH; Hanna M; Keltai M; Parkhomenko A; López-Sendón JL; Lopes RD; Siegbahn A; Granger CB; Wallentin L JAMA Cardiol; 2016 Jul; 1(4):451-60. PubMed ID: 27438322 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]